Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Urinary Bladder Neoplasms 5Melanoma 2Glioblastoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Ganglioneuroblastoma 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1

Interventions

Temozolomide 5Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2vocimagene amiretrorepvec 1trametinib 1dabrafenib 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Standard of Care 1Spinal Puncture 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiation 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1Outcome Assessment, Health Care 1Observational Studies as Topic 1Ketoconazole 1Irinotecan 1Heart Rate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Diphtheria-Tetanus Vaccine 1DNA 1Craniotomy 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × Transurethral Resection of Bladder × 90 days × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡